CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 271 enrolled
Drug / intervention
Meningococcal vaccine GSK134612 (Nimenrix)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00661557
NCT00661557Phase 2Completed
CompareCT.gov

Immunogenicity & Safety Study of GSK Biologicals' Meningococcal Vaccine GSK134612 Administered in Healthy Subjects Either Previously Primed With Mencevax™ ACWY or naïve to Meningococcal Vaccination.

GlaxoSmithKline·interventional·Posted Apr 18, 2008·Updated Dec 28, 2018

In Brief

A Phase 2 clinical trial evaluating Meningococcal vaccine GSK134612 (Nimenrix) for Infections, Meningococcal. Completed, enrolled 271 participants across 1 site.

Detailed Summary

In this study, subjects who were vaccinated with a meningococcal polysaccharide vaccine in a previous study (whose objectives \& outcome measures are presented in a separate protocol posting with NCT number = 00227422) will be vaccinated with a new vaccine using conjugation technology. These subjects will be compared to subjects vaccinated with the new vaccine, but who were not previously vaccinated with a meningococcal polysaccharide vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Meningococcal
CountriesLebanon
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 18, 2008
Enrollment StartMay 19, 2008
Primary CompletionDec 19, 2008
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.2 years ago

Interventions

Meningococcal vaccine GSK134612 (Nimenrix)biological

one dose, as intramuscular injection